Management of Electrolyte Abnormalities in Adrenal Insufficiency

Introduction to Mineralocorticoid Replacement Therapy

• The American College of Physicians recommends considering fludrocortisone dose reduction if hypertension or edema is present, and reducing the dose to 0.05 mg daily 1
• The Endocrine Society suggests maintaining the current prednisone dose (5 mg daily) as an appropriate maintenance dose for adrenal insufficiency, and not increasing it to compensate for mineralocorticoid effects 2
• Mineralocorticoid replacement is vital for maintaining blood pressure, water, and electrolyte homeostasis in patients with adrenal insufficiency, with fludrocortisone being a common replacement therapy 1

Monitoring and Management of Electrolyte Abnormalities

• Regular electrolyte checks should be performed every 1-3 months, and plasma renin activity (PRA) should be used to guide fludrocortisone dosing, with a target in the upper half of the reference range 1
• Annual comprehensive assessments should include electrolytes, glucose, and blood pressure, as recommended by the American College of Internal Medicine 1
• Patients should be instructed to report symptoms of electrolyte imbalances, and emphasis should be placed on the importance of medication adherence and regular monitoring, as well as stress dosing of glucocorticoids during illness 1
• Careful monitoring is essential to detect early signs of mineralocorticoid deficiency, including serum sodium and potassium levels, blood pressure in both supine and standing positions, presence of salt cravings or lightheadedness, and plasma renin activity (PRA) - target in upper half of reference range 1, 3
• More frequent monitoring is recommended for patients with a history of adrenal crisis, concurrent illness, or medication changes affecting fluid/electrolyte balance 3

Dose Adjustment and Management of Side Effects

• Under-replacement with fludrocortisone is common and may predispose patients to recurrent adrenal crises, while over-replacement can lead to hypertension and edema 1
• To minimize the risk of hyponatremia when decreasing fludrocortisone, reduce dose gradually over 4-6 weeks (typically by 0.05 mg every 1-2 weeks), allow 1-2 weeks at each dose level to assess for symptoms, monitor electrolytes regularly during the tapering process, and advise unrestricted sodium intake during tapering 1, 3
• If hyponatremia develops, return to the last effective dose of fludrocortisone, increase sodium intake, consider that the patient may require maintenance at the lowest effective dose rather than complete discontinuation, and in severe cases, hospitalization and IV sodium replacement may be necessary 1
• If symptoms of mineralocorticoid deficiency develop after complete discontinuation, the medication should be restarted at the last effective dose, and consideration should be given to maintenance at the lowest effective dose rather than complete discontinuation 3
• Consider reducing the dose of fludrocortisone when used with IV steroids to minimize potential side effects, although the optimal dose adjustment strategy is not well established 4
• Both fludrocortisone and intravenous steroids can cause hyperglycemia, and combined use may worsen glucose control, highlighting the need for regular blood glucose checks, especially in diabetic patients, as recommended by the American Diabetes Association 4
• Regular glucose monitoring is essential to prevent hyperglycemia, with the Endocrine Society suggesting close monitoring in patients receiving combined therapy 4

Dietary Recommendations and Interactions

• The patient should be recommended to have adequate sodium intake to balance mineralocorticoid effects, as suggested by the Journal of Internal Medicine 1
• Medications that interact with fludrocortisone (diuretics, acetazolamide, carbenoxolone, licorice, NSAIDs) should be avoided during tapering, as recommended by the Journal of Internal Medicine guidelines 1
• The following medications interact with fludrocortisone:

Special Populations and Contraindications

• Special populations, such as pregnant women, may require higher doses of fludrocortisone, up to 500 μg daily, in the third trimester, and those using drospirenone-containing contraceptives may also require increased doses, as recommended by the Journal of Internal Medicine 1
• Over-replacement with glucocorticoids to compensate for mineralocorticoid under-replacement should be avoided, as warned by the Journal of Internal Medicine 1
• Stopping mineralocorticoid replacement for essential hypertension is not recommended; instead, vasodilators should be used, as advised by the Journal of Internal Medicine 1
• Glucocorticoids should always be tapered separately from fludrocortisone, as recommended by the Journal of Clinical Oncology guidelines 3